Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $35.71

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned an average rating of “Buy” from the nine research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.71.

A number of research firms recently commented on DAWN. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st.

Day One Biopharmaceuticals Trading Down 0.2 %

NASDAQ DAWN opened at $12.87 on Monday. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -12.50 and a beta of -1.51. The business’s 50 day moving average is $13.86 and its two-hundred day moving average is $14.02. Day One Biopharmaceuticals has a 12-month low of $11.94 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the previous year, the company posted ($0.54) EPS. Equities analysts forecast that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 11,245 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $16.03, for a total value of $180,257.35. Following the transaction, the insider now directly owns 1,085,790 shares in the company, valued at approximately $17,405,213.70. This represents a 1.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 51,745 shares of company stock worth $748,567. 8.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently modified their holdings of the company. First Turn Management LLC purchased a new stake in Day One Biopharmaceuticals in the 3rd quarter worth approximately $13,204,000. GSA Capital Partners LLP purchased a new stake in shares of Day One Biopharmaceuticals in the third quarter valued at $825,000. Algert Global LLC increased its stake in Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company’s stock valued at $996,000 after purchasing an additional 50,990 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Day One Biopharmaceuticals by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after buying an additional 64,700 shares during the period. Finally, Vestal Point Capital LP boosted its stake in Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after buying an additional 1,250,000 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.